See "Specific therapies in CLL: mechanisms of resistance and strategies for administration" on webpage 471.Pretty just lately, preliminary final results from a third demo comparing ibrutinib compared to observation had been introduced.a hundred and five Sufferers receiving ibrutinib had an extended occasion-absolutely free survival, but no Over-all